Research programme: immunological nanoantibodies - Allele Biotechnology and Pharmaceuticals
Alternative Names: ALL-I-0143Latest Information Update: 28 Apr 2023
At a glance
- Originator Allele Biotechnology and Pharmaceuticals
- Class Anti-inflammatories; Single-domain antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Sepsis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 Apr 2023 No recent reports of development identified for preclinical development in Sepsis in USA
- 14 Mar 2019 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route) (Allele Biotechnology and Pharmaceuticals pipeline, March 2019)